Skip to main content

Sitting Too Much May Boost Odds of Dying

March 26, 2012 — Don't take this sitting down, but spending too much time in a chair is bad for your health -- really, really bad.
New research published in the Archives of Internal Medicine shows that people who spend a lot of time sitting may be up to 40% more likely to die from any cause, compared to people who don't sit as long.
The study tracked nearly 222,500 Australian adults for about three years. During that time, people's odds of dying dovetailed with how much time they spent sitting.
Compared to people who spent less than four hours per day sitting, the odds of dying were:
  • 15% higher for people who sat for at least eight hours
  • 40% higher for people who sat for 11 or more hours a day
“Our findings add to the mounting evidence that public health programs should focus not just on increasing population physical activity levels, but also on reducing sitting time,” the researchers write.
Alpa V. Patel, PhD, has published studies on the health risks associated with too much sitting. She is an epidemiologist at the American Cancer Society in Atlanta. “We are continuing to demonstrate time and time again in different populations that there is something real to the association between sitting time and reduced longevity.”
Get Up Out of That Chair
What's so bad about sitting for long periods? That's not totally clear. But exercise and movement do have a positive effect on blood fats called triglycerides and other heart risks, and improves blood pressure, Patel says.
Her advice: Sit for five fewer minutes per hour. “Small changes can have a big impact," she says.
Technology may fight that. It's given us fewer reasons to move, says David A. Friedman, MD. He is the chief of heart failure services at North Shore Plainview Hospital in Plainview, N.Y.
Instead of texting or emailing a colleague, “walk down a few cubicles and say, ‘Hi, how are you?’ This is good face time and it’s also good exercise.”
Olveen Carrasquillo, MD, MPH, is the chief of the division of general internal medicine at the University of Miami’s Miller School of Medicine. “A sedentary lifestyle is not good for your health,” he says. “Today we don’t even have to leave the house to go to the bank or mail a letter.”
The new study doesn't prove that sitting killed people. It's not clear which came first -- poorer health or spending more time in a chair.
Still, there's no doubt that movement is good for many reasons.
“It is hard to say whether someone is fairly sedentary because they are inactive or if they are inactive because of other things, such as an unhealthy lifestyle that includes smoking," says Scott Kahan, MD, MPH. He is the director of the National Center for Weight and Wellness in Washington, D.C.
Still, there is no doubt that being active is healthy. “The key is to do something you like to do, whether it’s sports, going to the gym, walking, or gardening. “If it is terribly unenjoyable, the likelihood of sustaining it is pretty low.”
SOURCES:
Van der Ploeg, H. Archives of Internal Medicine, 2012.
Dunstan, D. Archives of Internal Medicine, 2012.
Scott Kahan, MD, MPH, director, National Center for Weight and Wellness, Washington D.C.
David A. Friedman, MD, chief of heart failure services, North Shore Plainview Hospital, Plainview, N.Y.
Alpa V. Patel, PhD, epidemiologist, American Cancer Society, Atlanta, Ga.
Olveen Carrasquillo, MD, chief, division of general medicine, University of Miami Miller School of Medicine, Miami, Fla.

Authors and Disclosures

Journalist

Denise Mann

Denise Mann is a freelance medical writer.

Comments

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Fake drugs given to NHS patients still untraced

Only eight people out of several thousand who received counterfeit drugs from the NHS in an incident in 2007 have been identified. Of those eight, only three have been informed about the incident, a BBC investigation has learned. 72,000 packs of counterfeit drugs entered the UK supply chain in 2007 but 25,000 remain untraced. The regulator, the MHRA, has said it took swift action in 2007 and issued its "most serious recall notice". A new EU directive will further improve patient safety, it added. In the spring of 2007, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an emergency recall of drugs which had been identified as counterfeit. Those recalled included batches of the prostate cancer drug Casodex; of a drug used to treat heart complaints called Plavix; and of Zyprexa, which is used to control the symptoms of schizophrenia. The MHRA successfully seized 40,000 packs before they were distributed to pharmacies but 25,000 reached chemists acros...

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...